23rd February 2017

Hospital Resource Use

TARGAXAN® has been shown to reduce the burden on healthcare systems when used to prevent the recurrence of overt hepatic encephalopathy 1‑3

The use of rifaximin-α to manage UK & Irish patients with hepatic encephalopathy has shown reductions in hospital resource utilisation. Select a parameter to find out more.

UK/XIF5/0719/0523  DOP: October 2019

References

  1. Orr J G, Currie C J et al. Liver Int 2016;36:1295-1303
  2. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792
  3. Hudson M, et al. Frontline Gastroenterology. Published Online First: 07-April-2017. doi:10.1136/flgastro-2016-100792 Supplementary Material